25 September 2024
Appointment of Non-Executive Director
Rentokil Initial plc (FTSE: RTO, "the Company") today announces the appointment of Brian Baldwin to its Board as a Non-Executive Director with effect from 1 October 2024. He will also become a member of the Nomination Committee and Remuneration Committee from this date.
Mr. Baldwin is the Head of Research of Trian Fund Management, L.P. ("Trian"), an investment management firm. Mr Baldwin has been a Trian Partner since 2013 and a member of Trian's Investment Team since 2007. He has played leadership roles in many of Trian's investments.
Mr. Baldwin has been a non-executive director of Janus Henderson Group plc since 2022 and currently serves on the Board's Nominating and Corporate Governance Committee and the Risk Committee. From 2018 to 2020, he served as a director and member of the Compensation and Governance Committees of nVent Electric plc (formerly the electrical business of Pentair plc before becoming a standalone public company).
Prior to joining Trian, Mr. Baldwin was an analyst at Merrill Lynch Global Private Equity from 2005 to 2007. Mr. Baldwin received a B.S. degree, summa cum laude, from The Wharton School at the University of
Richard Solomons, Chairman of Rentokil Initial, said:
"We are delighted to welcome Brian to the Board of Rentokil Initial and we look forward to working with him to deliver long-term sustainable value for our shareholders and, in particular, executing our plans to integrate the Terminix business and to increase organic growth in our
Brian Baldwin said:
"I welcome the opportunity to join the Board of Rentokil Initial. Trian believes Rentokil has significant potential and runway for growth that can be achieved by leveraging its strong brands and market leading positions, particularly in the US. I look forward to working with management and the Board to identify options to help drive long-term value that will benefit all stakeholders."
Trian has confirmed to the Company that it manages investment vehicles owning approximately 57.1 million shares of Rentokil Initial (approximately 2.26% of shares outstanding).
There are no further details to be disclosed relating to Brian Baldwin under Section 6.4.8 of the
For further information please contact:
Rentokil Initial plc
Investors |
Peter Russell |
07795 166506 |
Media |
Malcolm Padley |
07788 978 199 |
Company Secretary |
Rachel Canham |
01293 858 000 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.